Stabilized recombinant trefoil factor 2 (TFF2-CTP) enhances anti-tumor activity of PD-1 blockade in mouse models of colorectal cancer

被引：0
|
作者：
Kim, Woosook [1 ]
Fu, Na [1 ]
Duddempudi, Phaneendra [2 ]
Dubeykovskaya, Zinaida [3 ]
Almo, Steven [2 ]
Guha, Chandan [2 ]
Lederman, Seth [4 ]
Wang, Timothy [1 ]
机构：
[1] Columbia Univ, Med Ctr, New York, NY USA
[2] Albert Einstein Coll Med, New York, NY USA
[3] NYU, New York, NY USA
[4] Tonix Pharmaceut Inc, New York, NY USA
来源：
CANCER RESEARCH | 2020年 / 80卷 / 16期
关键词：
D O I：
10.1158/1538-7445.AM2020-6640
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6640
引用
收藏
页数：2
相关论文
共 50 条
  • [21] CD47 BLOCKADE SYNERGIZES WITH PD-1 CHECKPOINT INHIBITOR AND ENHANCES ANTI-TUMOR EFFICACY IN HEPATOCELLULAR CARCINOMA
    Kang, Wonseok
    Kim, Ji-Young
    Yang, Sera
    Kang, Sohee
    Paik, Yong-Han
    HEPATOLOGY, 2019, 70 : 1199A - 1200A
  • [22] Rovalpituzumab tesirine enhances the anti-tumor efficacy of PD-1 blockade in a murine model of small cell lung cancer with endogenous 0113 expression
    Vitorno, Philip M.
    Chuang, Chen-Hua
    Moore, Christine
    Turan, Tolga
    Ferrando, Ronald
    Nichols, Aaron
    Madhavan, Shravanthi
    Saunders, Laura R.
    CANCER RESEARCH, 2019, 79 (13)
  • [23] Entinostat enhances antitumor immune responses and cooperates with PD-1 blockade in bladder cancer mouse models.
    Truong, Andrew S.
    Zhou, Mi
    Utsumi, Takanobu
    Krishnan, Bhavani
    Stewart, Kyle G.
    Saito, Ryoichi
    Manocha, Ujjawal
    Bailey, Sean T.
    Kim, William Y.
    CLINICAL CANCER RESEARCH, 2020, 26 (15) : 37 - 37
  • [24] Anlotinib optimizes anti-tumor innate immunity to potentiate the therapeutic effect of PD-1 blockade in lung cancer
    Yinli Yang
    Ling Li
    Zhansheng Jiang
    Bin Wang
    Zhanyu Pan
    Cancer Immunology, Immunotherapy, 2020, 69 : 2523 - 2532
  • [25] Anlotinib optimizes anti-tumor innate immunity to potentiate the therapeutic effect of PD-1 blockade in lung cancer
    Yang, Yinli
    Li, Ling
    Jiang, Zhansheng
    Wang, Bin
    Pan, Zhanyu
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2020, 69 (12) : 2523 - 2532
  • [26] Combination of EGFR antibody with PD-1 pathway inhibitors improves anti-tumor efficacy and enhances intra-tumor immune response in preclinical mouse tumor models
    Kandaswamy, Veena
    Forest, Amelie
    Deroose, Marianne
    Schaer, David A.
    Chen, Ting
    Liu, Shengwu
    Surguladze, David
    Yao, Yung-mae
    Doman, Thompson
    Hall, Gerald
    Wong, Kwok-Kin
    Kalos, Michael
    Novosiadly, Ruslan D.
    CANCER RESEARCH, 2018, 78 (13)
  • [27] Anti-PD-1 and VEGFR2 blockade induces vascular normalization and enhances anti-tumor immune responses in HCC
    Shigeta, Kohei
    Matsui, Aya
    Aoki, Shuichi
    Kitagawa, Yuko
    CANCER SCIENCE, 2021, 112 : 397 - 397
  • [28] Selinexor, a selective inhibitor of nuclear export (SINE) compound, shows synergistic anti-tumor activity when combined with PD-1 blockade in a mouse model of colon cancer
    Elloul, Sivan
    Chang, Hua
    Klebanov, Boris
    Kashyap, Trinayan
    Werman, Maxwell
    Lee, Margaret
    Landesman, Yosef
    Shacham, Sharon
    Kauffman, Michael
    Friedlander, Sharon Y.
    CANCER RESEARCH, 2016, 76
  • [29] Combination of IL-33 with PD-1 blockade augment mILC2s-mediated anti-tumor immunity
    Jiawei Yue
    Hui Guo
    Peng Xu
    Jinhong Ma
    Weifeng Shi
    Yumin Wu
    Cancer Immunology, Immunotherapy, 73
  • [30] Combination of IL-33 with PD-1 blockade augment mILC2s-mediated anti-tumor immunity
    Yue, Jiawei
    Guo, Hui
    Xu, Peng
    Ma, Jinhong
    Shi, Weifeng
    Wu, Yumin
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2024, 73 (04)
12345